Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated DiseaseClaire L. Langrish, Philip A. Nunn|The Journal of Immunology|2021Cited by 121